Nonsense!!! It's Aspire that's made shareholder wealth possible!!!
All pre-revenue biotech companies have to get funding from somewhere, and IPIX's deal with Aspire has been an excellent choice. Without funding IPIX would not have been able to afford the platform development and clinical trials that make it the company on the threshold of greatness that it is today.